Thomas Steuber, is a faculty member of the Martini-Clinic in the Prostate Cancer Centre at the University Hospital Hamburg-Eppendorf, Hamburg, Germany, and is Assistant Professor of urological oncology since 2008. Prof. Steuber obtained his medical degree, in 1997, from the University Hospital Hamburg-Eppendorf. He completed his urological clinical residency/fellowship at the Department of Urology and Urological Oncology at the University Hospital Hamburg-Eppendorf (1997−2004), followed by a research fellowship in urological oncology at the Memorial Sloan-Kettering Cancer Center in New York, NY, US (2004−2005).
Prof. Steuber’s clinical work focuses on surgical (open and robotic-assisted) and medical treatment of localised and metastatic prostate cancer. His scientific interests include on prostate cancer biomarkers, the evaluation of risk prediction tools, and clinical trials on outcomes of oligometastatic cancer patients. Prof. Steuber was the institutional Principal Investigator in all pivotal studies of abiraterone acetate in castration resistant and hormone naive metastatic prostate cancer and has treated a large cohort of castration resistant prostate cancer patients in the German abiraterone acetate Compassionate Use Programme. He is a member of the European and German Associations of Urology, has been awarded a Young Investigator Award from the National Urological Association in Germany, and is recipient of several international awards for posters.
Prof. Steuber has co-authored more than 138 peer-reviewed articles and 80 abstracts, and is a regular reviewer for The Journal of Urology, European Urology, and the British Journal of Urology International.